Related Experiment Videos
Recent progress in the use of monoclonal antibodies for imaging and therapy
1Academic Surgical Unit, Imperial College of Science, Technology and Medicine, St. Mary's Hospital, London, UK.
Abstract:
Despite their availability since 1975, monoclonal antibodies (MAbs) have failed to make a significant impact in the clinical treatment of patients outside of diagnostic assays for the measurement of tumor markers. Recently, however, studies have appeared demonstrating that MAb-directed imaging techniques may have a meaningful role to play in the diagnosis and treatment of patients with solid tumors such as colorectal cancer and malignant melanoma. Furthermore, second generation MAbs are appearing that mediate more specific binding characteristics, and experimental studies have suggested that genuine antitumor activity may not be far away. Finally, the recent development of newer molecules, such as chimeric and human antibodies, may lead to significant advances in MAb use. Specifically, allergic reactions to murine antibodies can be reduced or avoided altogether, and repeated doses can be administered safely. These newer MAbs appear to mediate cell lysis more efficiently and have been combined with chemotherapeutic agents and cell toxins. Greater understanding of host responses to MAbs and the development of anti-idiotype and anti-anti-idiotype antibodies have led to clinical trials that, it is hoped, will confirm the place of MAb therapy in clinical oncology.
Insights
Monoclonal antibodies (MAbs) show promise in diagnosing and treating solid tumors. Newer MAb types, like chimeric and human antibodies, reduce allergic reactions and enhance antitumor activity, paving the way for clinical oncology applications.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (MAbs), available since 1975, have been primarily used in diagnostic assays for tumor markers.
- Their clinical impact in patient treatment, particularly for solid tumors, has been limited until recently.
Purpose of the Study:
- To explore the evolving role of monoclonal antibodies (MAbs) in the diagnosis and treatment of solid tumors.
- To highlight advancements in MAb technology, including second-generation, chimeric, and human antibodies.
- To discuss the potential of MAbs in enhancing antitumor activity and reducing adverse effects.
Main Methods:
- Review of recent studies on MAb-directed imaging techniques for solid tumors like colorectal cancer and malignant melanoma.
- Analysis of experimental data on second-generation MAbs with improved binding specificity.
- Examination of the development and application of chimeric and human antibodies to mitigate allergic reactions and improve safety.
- Investigation of MAb combinations with chemotherapeutic agents and cell toxins.
- Consideration of host responses to MAbs and development of anti-idiotype antibodies.
Main Results:
- MAb-directed imaging shows potential in diagnosing and treating solid tumors.
- Second-generation MAbs exhibit enhanced specificity, with potential for direct antitumor activity.
- Chimeric and human antibodies reduce allergic reactions, enabling safer, repeated dosing.
- Novel MAbs demonstrate improved cell lysis efficiency and synergistic effects with chemotherapeutics and toxins.
Conclusions:
- Monoclonal antibody therapy is poised to become a significant tool in clinical oncology.
- Advancements in MAb engineering and understanding of host responses are driving progress.
- Ongoing clinical trials are expected to validate the efficacy of MAb therapy for various cancers.